Forum Agenda
-
Medicine-Engineering Integration and Innovative Medical Devices
-
China’s Innovation Ecosystem and Models
-
Research Translation and Early-stage Project Incubation Meeting
-
Accelerating Innovation Through External Collaboration Meeting
-
Leveraging China's Innovation to Accelerate Global Drug R&D Meeting
-
USTC Original Innovation Power: Alumni Enterprise Innovation Matrix Meeting
-
Clinical Translation of Medical Research Achievements Meeting
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
JunHe LLP Session:New Models of Cross-Border Pharmaceutical Cooperation Session
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Nanobody Drug R&D Session
Stay tuned
Opening Remarks
Changchun Zha:Chairman, Biointron
Progress of Nanobody‑based Therapeutics & Applications in ADCs
Haikun Shi: Founder & Chairman, Kunyu Biotech
Development of Nanobody Therapeutics for Diabetic Nephropathy
Jiajun Fan: Director & Principal Investigator, Institute of Biotech Pharmaceuticals, Quzhou Fuda Biomedical Innovation Institute; Shanghai RisingStar Young Scientist
Dual-Epitope Nanobodies for Acute Disease Therapy Strategies
Mingyue Huang: Founder, Chairman & CEO, BiyoPharma
Applications of Diverse Screening Platforms in Nanobody Discovery
Lei Shi: Senior Vice President, Biointron
Roundtable: Challenges and Future of Next‑Generation Antibody Drugs
Moderator: Haikun Shi: Founder & Chairman, Kunyu Biotech
Shuqing Chen: Professor & Doctoral Supervisor, College of Pharmaceutical Sciences, Zhejiang University; Founder & Chairman, Neoantigen
Jun Wang: General Manager,Jushi Biotech,CSPC Pharmaceutical Group
Tao Xu: Founder & CEO, SmartNuclide
Jing Huang: COO & CBO, Novamab
Mingyue Huang: Founder, Chairman & CEO, BiyoPharma